Sitemap
Pages
- Get In Touch
- Competitive Intelligence In Oncology
- Competitive Intelligence For Rare Disease Specialists
- Life Science Consultancy
- Pharmaceutical Competitive Intelligence
- Healthcare Competitive Intelligence
- Cookie Policy
- Privacy Policy
- Request for Proposal
- Contact
- Subscribe
- Careers
- How we work
- What we do
- Who we are
- Sitemap
- News
- Home
Posts
News
- The Copycat Market: Season of Migration to the East?
- Jeanne Penn joins Cambridge Healthcare Research as Vice President, US Commercial for Solici
- Bispecifics: A breath of fresh air for th2 respiratory disease?
- Inflammatory Bowl Disease (IBD): Who is your money on?
- Cinderella 2: Unlocking the value chain in antibiotic development to achieve market success
- Triple threat: Is the era of trispecific biologics upon us in Immunology?
- Flashing a Spotlight on the ‘Hot’ Topic of Menopause
- Is Rheumatoid Arthritis going to have a déjà vu moment?
- Gene Therapy and nAMD: Can We Move Beyond the Needle?
- The mRNA revolution: How 30 years of research sparked an overnight success
- Tech to Triumph: Can the Technology Shape Gene Therapy Success?
- Advancing the Cure: The Road to Accessible SCD Therapies
- Prostate Cancer Q&A: ‘See’quencing the future of treatment options
- ASCO 2024: Are you ready for the Oncology Event-of-the-Year?
- Gene Therapy and nAMD: Can We Move Beyond the Needle?
- The changing seasons of Rheumatoid Arthritis – can RA drugs bloom again?
- Who let the Gene Therapies out? Unleashing GTs’ Power in Rare Disorders
- Tipping the scales in Obesity – are GLP-1R developers overreaching?
- Contraceptives: is current policy hiding a golden opportunity?
- Redefining Precision – The Next Chapter in ADC Optimization
- The ABC of ADCs
- Unlocking Migraine Prevention: A 5-Year Journey Through the CGRP Revolution and a Look Towards What’s Next
- PharmaCI USA 2023: How CI should stay ahead of the curve to remain the foundation of Pharma Strategy
- Eco-Friendly Medical Devices: Can We Improve?
- Cambridge Healthcare Research Appoints the Head of their Competitive Intelligence Division, Solici.
- ESG Trends in Pharma: Trends and Driving Factors
- Webinar: Navigating the complex therapy landscape
- The Many Facets of Sustainability in Pharma
- Complex Therapy Support Solutions – Evolution from Reactive to Disruptive
- Solici to host: Navigating the Complex Therapies Landscape (webinar)
- Pricing Complex Therapies: the role of Alternative Payment Models
- Solici is exhibiting at Pharma CI Europe
- Manufacturing Complex Therapies: the increasing relevance of automation
- Examining Complex Therapies: How Complex can a Therapy really be?
Resources
- Webinar: Navigating the complex therapy landscape
- Aduhelm, a revolutionary approval; mapping the road to the clinic
- The ‘what’ that matters – questions worth asking
- Telehealth: Tackling Evolving Competitive Landscapes in Response to a Megatrend
- Is Pre-Hospital Administration the Future for Antiplatelet Therapies?
- 15 Years of Biosimilars: Lessons Learnt and What’s Next
- Why war games are not the answer to understanding markets – Part Two
- The rise of real-world evidence in the pharmaceutical industry
- A view through the weeds: Where do we stand on medical cannabis
- Why war games are not the answer to understanding markets – Part One
- Review: Competitive Intelligence in Pharma and Life Science Event
- A Hidden Gen: The Billion Dollar US Generic Injectables Market
- Synthetic control arms – use of RWE in clinical trials
- Virtual Conferences: A Year in Review and Future Direction
- The war on vaccines in a post-COVID world
- Part II-Should Your Strategy be a Destination or a Journey
- Why 2021 Will Be A Fiercely Competitive Year In The Human Growth Hormone (hGH) Market
- Part I-Should Your Strategy Be A Destination Or A Journey?
- Unlocking the Opportunity in Axial Spondyloarthritis – Treating the Visible and the Invisible
- Could targeting lysosomal dysfunction be the key to treating Parkinson’s disease?
- China Market Access: Opportunity or Obstacle?
- Have ‘smart’ devices arrived in healthcare? The emergence of digitally connected combination products
- From cholesterol to COVID-19: RNA therapeutics as an emerging treatment approach
- Could CDK4/6 inhibitors be established in early-stage HR+ breast cancer?
- Cancer Cachexia – no time to waste
- The US Biosimilar Landscape is Heating Up
- The Gene Therapy Revolution Has Arrived. But What’s Next?
- Managing cancer patients during the COVID-19 pandemic
- COVID-19: Dissecting the therapeutic and vaccine landscape Volume II
- Hidden opportunity in a time of crisis: Rheumatology’s assets at the COVID-19 frontline
- COVID-19: Dissecting the therapeutic and vaccine landscape
- The Show Must Go On: Virtual conferences and primary insights
- Nexletol and Nexlizet approvals: a heart-warming price in a space defeated with pricing battles?
- Tumor Mutational Burden: end of the road or an uphill battle for acceptance as an immuno-oncology biomarker?
- Will PSMA-targeting diagnostics and therapeutics revolutionize Prostate Cancer care?
- CTAD Impressions: Is there finally going to be a disease modifying therapy approved for Alzheimer’s?
- Rapid Approvals & Innovative Approaches, But Which Sickle Cell Therapies Will Offer Real Benefits?
- Key Insights from ESMO 2019
- Two’s a crowd and three’s a party – managing a drug franchise
- Findacure Rare Disease Showcase
- Bio Asia Taiwan 2019 Highlights
Case Studies
- Enhancing our client’s competitive trial strategy
- Identifying opportunities for near-term business expansion in the field of surgical instruments through product distribution licensing
- Identifying and scoping potential opportunities to enter the digestive health space in the US and EU
- Comprehensive mapping of the hurdles and barriers to entry in the US and EU complex generic space
- Role-playing three key competitors to support brand planning in rare disease indications
- Supporting the launch preparation of lead assets
- Consolidating the successful launch of a blockbuster brand
- Market insights for the launch of a new hematology product in the US, EU and Japan
- Competitor and KOL insights to support the launch of a new neurodegenerative disease product
- Entering a new therapeutic space with an established product
- Preparing to launch a new treatment for a rare disease
- Supporting the launch strategy for a new oncology product
- Understanding requirements for label inclusion of home administration in Europe and the US
- Evaluating current lab practices for a specific diagnostic assay in key geographies
Team
- Matteo Perucchini
- Edward Cartwright
- Max Rubin
- Stephen Galt
- Brendan Walkden
- Jacky Kourieh
- Peter Donachie
- Nicole Estermann
- Aarti Ruparelia
- Diana Di Paolo
- John Acord
- Anamika Ghosh
- Vera Norberto Malheiro
- Rakshindh Sekhon
- Delyan Mutavchiev
- Raymond Lao
- Heather Baldie
- Maria Zygouropoulou
- Shruti Singla
- Nathaniel Ng
- Chrystalla Constantinou
- Constance Ito
- Ioanna Ferekidou
- Oliver Hemmings
- Rui Li
- Jessica Elmer